---
title: "Weekly Recap | Humana +4.15%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298098584.md"
description: "Humana rose 4.15% on the week to $401.54, outperforming the S&P 500 by roughly 4.06 percentage points. The stock started soft, dipping to $382.11 on Monday, then recovered through Tuesday to Thursday, reaching a weekly high of $413.495 before edging lower on Friday. The week’s range was 8.14%. Trading was thin: average daily volume of 954,110 shares came in about 22% below the 60-day median."
datetime: "2026-09-05T07:05:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298098584.md)
  - [en](https://longbridge.com/en/news/298098584.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298098584.md)
generator: "portal-rs"
---

# Weekly Recap | Humana +4.15%, consensus target above spot

## The Week

Humana rose 4.15% on the week to $401.54, outperforming the S&P 500 by roughly 4.06 percentage points. The stock started soft, dipping to $382.11 on Monday, then recovered through Tuesday to Thursday, reaching a weekly high of $413.495 before edging lower on Friday. The week’s range was 8.14%. Trading was thin: average daily volume of 954,110 shares came in about 22% below the 60-day median.

## Key Events

The week’s focus was on earnings guidance. On Tuesday, Humana reiterated fiscal 2026 GAAP EPS of at least $6.52 and adjusted EPS of at least $9.00, alongside the formal FY 2026 guidance release. On Wednesday, the company declared a quarterly dividend of $0.89. The same day, industry news highlighted that DaVita (DVA) expanded its partnership with Humana, extending their collaboration in managed care. Thursday brought a small institutional purchase, with Retireful LLC buying 3,146 shares. Separately, Bill Ackman’s public support for Mark Cuban’s drug pricing model drew attention to managed care names, with Humana among those discussed as potentially affected. On Friday, Humana underperformed peers.

## Analyst Ratings

Coverage stands at 26 institutions: 11 rate it buy, 1 rate it overweight, 13 rate it hold, and 1 rate it sell. The consensus rating is buy. The consensus target price is $418.61, about 4.25% above the last close. Targets are wide-ranging, from $280.00 to $513.00, suggesting divided views on the company’s earnings path. Within managed health care, Humana ranks second among 9 covered names.

## The Week Ahead

No Humana earnings are due next week, so macro data will steer sentiment. On Thursday, September 10, jobless claims, final demand PPI, and existing home sales are scheduled, with jobless claims expected at 205,000 and PPI month-on-month at 0.4%. Treasury auction metrics, including bid-to-cover, may also matter for rate-sensitive healthcare names. Humana’s next earnings release is set for November 6 pre-market.

## In Short

Humana closed above $400, supported by a consensus buy rating, though the wide target range leaves limited consensus upside. Latest-session flows showed small-lot money as a net seller while large-lot money was a net buyer. Valuation sits near 37.7x P/E and 2.51x P/B. The next test will be how macro data feeds into sector sentiment, and whether the November earnings report validates current guidance.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [HUM.US](https://longbridge.com/en/quote/HUM.US.md)

## Related News & Research

- [UnitedHealthcare, Aetna say 2027 Medicare Advantage plans to offer more limited provider networks](https://longbridge.com/en/news/300674124.md)
- [Envestnet Asset Management Inc. Increases Position in Humana Inc. $HUM](https://longbridge.com/en/news/300653680.md)
- [Humana Inc. (NYSE: HUM) Investor Alert: Securities Fraud Case Moves Forward Following 22% Stock Drop; Schubert Jonckheer Investigating](https://longbridge.com/en/news/301042636.md)
- [Ambea completes Humana takeover after reaching 90.84% acceptance level](https://longbridge.com/en/news/300694731.md)
- [BUZZ-Cantor upgrades Humana, sees strong Medicare margin recovery in 2027](https://longbridge.com/en/news/301133173.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**